351 related articles for article (PubMed ID: 35482908)
21. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
22. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
23. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
Germain ND; Chung WK; Sarmiere PD
Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
[TBL] [Abstract][Full Text] [Related]
24. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
[TBL] [Abstract][Full Text] [Related]
26. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
27. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
Aoki Y; Wood MJA
J Neuromuscul Dis; 2021; 8(6):869-884. PubMed ID: 34092651
[TBL] [Abstract][Full Text] [Related]
28. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets.
Klim JR; Vance C; Scotter EL
Int J Biochem Cell Biol; 2019 May; 110():149-153. PubMed ID: 30904737
[TBL] [Abstract][Full Text] [Related]
29. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
30. RNA therapeutics: RNAi and antisense mechanisms and clinical applications.
Chery J
Postdoc J; 2016 Jul; 4(7):35-50. PubMed ID: 27570789
[TBL] [Abstract][Full Text] [Related]
31. Antisense Oligonucleotides for the Study and Treatment of ALS.
Boros BD; Schoch KM; Kreple CJ; Miller TM
Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
[TBL] [Abstract][Full Text] [Related]
32. Silencing strategies for therapy of SOD1-mediated ALS.
van Zundert B; Brown RH
Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
[TBL] [Abstract][Full Text] [Related]
33. Treating hereditary transthyretin amyloidosis: Present & future challenges.
Echaniz-Laguna A; Cauquil C; Labeyrie C; Adams D
Rev Neurol (Paris); 2023; 179(1-2):30-34. PubMed ID: 36150937
[TBL] [Abstract][Full Text] [Related]
34. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.
Hu J; Rigo F; Prakash TP; Corey DR
Nucleic Acid Ther; 2017 Apr; 27(2):87-94. PubMed ID: 28005462
[TBL] [Abstract][Full Text] [Related]
35. Challenges and Opportunities for Nucleic Acid Therapeutics.
Corey DR; Damha MJ; Manoharan M
Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1
Duan C; Kang M; Pan X; Gan Z; Huang V; Li G; Place RF; Li LC
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102147. PubMed ID: 38435120
[TBL] [Abstract][Full Text] [Related]
37. The infinite possibilities of RNA therapeutics.
Mollocana-Lara EC; Ni M; Agathos SN; Gonzales-Zubiate FA
J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34463324
[TBL] [Abstract][Full Text] [Related]
38. Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy.
Hammond SM; Abendroth F; Goli L; Stoodley J; Burrell M; Thom G; Gurrell I; Ahlskog N; Gait MJ; Wood MJ; Webster CI
JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36346674
[TBL] [Abstract][Full Text] [Related]
39. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
40. Gene therapy for ALS: A review.
Amado DA; Davidson BL
Mol Ther; 2021 Dec; 29(12):3345-3358. PubMed ID: 33839324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
